Red Sea freight disruption impact
Increased transit times and freight costs due to Red Sea crisis could add ~INR 30 crore to expenses, potentially pressuring margins.
medium · management_commentaryAjanta Pharma Limited — Q4 FY24
Ajanta Pharma delivered a strong Q4 FY24 with revenue of INR 1,054 crore (+20% YoY), EBITDA of INR 278 crore (+86% YoY), and PAT of INR 203 crore (+66% YoY).
bullish
high
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
US price erosion may be higher than guided
An analyst questioned whether high single-digit price erosion is aggressive; management acknowledged it's their estimate but could be worse.
medium · analyst_questionInstitutional business unpredictability
Africa institutional business (antimalarials) is lumpy and dependent on procurement agency schedules; Q4 benefited from preponed orders, which may not recur.
medium · management_commentaryM&A valuations remain high for premium assets
Management noted that while valuations have tapered, premium specialty portfolios are still expensive, limiting inorganic growth options.
low · analyst_question